세계의 의료기기 임상시험 시장 규모, 점유율, 동향 분석 보고서 : 연구 유형별, 연구 디자인별, 적응증별, 지역별, 부문 예측(2025-2030년)

Medical Device Clinical Trials Market Size, Share & Trends Analysis Report By Study Type, By Study Design, By Indication, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,272,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,662,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,443,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

의료기기 임상시험 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 의료기기 임상시험 시장 규모는 2030년까지 235억 3,000만 달러에 달하고, 2025-2030년 연평균 6.18%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

임상시험 수 증가, R&D 투자 확대, 기기 검증에 대한 규제 요건 강화 등이 이 시장을 주도하고 있습니다. 또한, AI 기반 분석, 자동화, 디지털 플랫폼 등 끊임없는 기술 발전은 환자 모집, 실시간 모니터링, 데이터 분석을 최적화하여 임상시험의 효율성을 혁신적으로 개선하고 있습니다. 머신러닝, 분산형 시험 모델, 웨어러블 기술의 통합은 시험의 정확성을 더욱 높이고 비용을 절감하고 있습니다.

또한, 임상시험에서 웨어러블 기기와 디지털 바이오마커의 통합이 진행됨에 따라 지속적인 실생활에서의 건강 추적이 가능해지면서 환자 모니터링과 데이터 수집이 크게 변화하고 있습니다. 스마트워치, 바이오센서, 원격 건강 추적기 등의 기기가 실시간 생리적 데이터를 제공함으로써 연구자들은 임상 환경 밖에서도 환자를 모니터링할 수 있게 되었고, 시험의 정확도가 향상되었으며, 잦은 병원 방문의 필요성이 줄어들었습니다. 이러한 발전으로 인해 분산형 임상시험과 하이브리드 임상시험이 널리 채택되고 있으며, 특히 원격지나 의료서비스가 부족한 지역의 환자들을 중심으로 더 많은 환자 참여가 가능해졌습니다.

또한, 개인 맞춤형 의료 및 환자 맞춤형 치료 접근 방식으로의 전환은 특히 정형외과, 심장병학, 종양학 등의 분야에서 맞춤형 의료기기에 대한 수요를 크게 증가시켰습니다. 맞춤형 치료의 중요성이 강조되면서 개별 환자의 요구에 맞게 설계된 의료기기의 개발이 필요하게 되었고, 적응증 설계에 초점을 맞춘 임상시험이 증가하게 되었습니다. 3D 프린팅, AI 기반 진단, 생체재료공학의 발전으로 의료기기 제조업체들은 고도로 개인화된 임플란트, 인공관절, 인공관절 등 다양한 의료기기를 개발할 수 있게 되었습니다. 임플란트, 인공장기, 약물과 기기의 조합을 만들 수 있는 능력을 확대하고 있습니다.

의료기기 임상시험 시장에서의 입지를 강화하기 위해 주요 기업들은 전략적 파트너십, 제품 혁신, 규제 당국의 승인, 지리적 확장, AI 기반 임상시험 솔루션 등을 통해 시장에서의 입지를 강화해 나가고 있습니다. Medtronic 및 Siemens Healthineers와 같은 기업은 AI 기반 임상시험 생태계를 확장하고 있으며, Abbott는 환자 관리를 강화하기 위해 Heartmate 3 LVAD의 라벨 업데이트에 대한 FDA 승인을 확보했습니다.

의료기기 임상시험 시장 보고서 하이라이트:

• 시험 유형별로는 피벗 테스트가 규제 당국의 승인 획득에 중요한 역할을 하기 때문에 피벗 테스트가 시장을 주도하고 있습니다. 피벗얼 시험은 안전성과 유효성에 대한 종합적인 데이터를 제공하며, 의료기기가 상용화되기 전 마지막 단계의 역할을 합니다.
• 시험 설계에 따라 2024년에는 중재 시험이 가장 큰 매출 점유율을 차지했습니다. 중재 시험은 특히 심장학, 정형외과, 신경학 등 고위험 장비에 대한 규제 당국의 승인을 얻기 위해 필수적입니다.
• 적응증별로는 심혈관 질환(CVDs)의 세계 부담과 이식형 심장 장치, 스텐트, 판막 교체 기술의 지속적인 혁신으로 인해 심혈관 장치가 2024년 가장 큰 매출 점유율을 차지했습니다.
• 지역별로는 북미가 강력한 임상 연구 인프라, 높은 R&D 투자, 주요 제약사 및 생명공학 기업의 존재로 인해 2024년에 지배적인 위치를 차지했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 동향과 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 기술 진보
  • AI와 디지털 기술 통합
• 가격 모델 분석
• 임상시험 건수 분석, 2024년
• 업계 분석 툴
  • Porter의 Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 의료기기 임상시험 시장 : 연구 유형 추정·동향 분석

• 부문 대시보드
• 의료기기 임상시험 시장 : 연구 유형 변동 분석
• 의료기기 임상시험 규모와 동향 분석(연구 유형별, 2018-2030년)
• 실현 가능성과 파일럿 스터디
• 중요 연구
• FDA PMA 신청
• 승인 후 조사

제5장 의료기기 임상시험 시장 : 연구 디자인 추정·동향 분석

• 부문 대시보드
• 의료기기 임상시험 시장 : 연구 설계 변동 분석
• 의료기기 임상시험 규모와 동향 분석(연구 디자인별, 2018-2030년)
• 개입적
• 관찰적
• 확장 액세스

제6장 의료기기 임상시험 시장 : 적응증 추정·동향 분석

• 부문 대시보드
• 의료기기 임상시험 시장 : 적응증 변동 분석
• 의료기기 임상시험 규모와 동향 분석(적응증별, 2018-2030년)
• 심장혈관 기기
• 신경학 기기
• 정형외과 기기
• 진단 영상
• 마취 및 호흡기 기기
• 기타

제7장 의료기기 임상시험 시장 : 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모와 예측 및 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 기업 분류
• 기업 시장 현황 분석, 2024년
• 기업 개요
  • Abbott
  • Medtronic
  • Siemens Healthineers AG
  • Fresenius Medical Care AG
  • GE Healthcare
  • Koninklijke Philips NV
  • Danaher Corporation
  • Baxter
  • Boston Scientific Corporation
  • F. Hoffmann La Roche

LSH

영문 목차

영문목차

Medical Device Clinical Trials Market Growth & Trends:

The global medical device clinical trials market size is expected to reach USD 23.53 billion by 2030, and is anticipated to grow at a CAGR of 6.18% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by a rising number of clinical trials, growing R&D investments, and regulatory requirements for device validation. In addition, constant technological advancements, such as AI-driven analytics, automation, and digital platforms, are revolutionizing trial efficiency by optimizing patient recruitment, real-time monitoring, and data analysis. The integration of machine learning, decentralized trial models, and wearable technology is further enhancing trial accuracy and reducing costs.

Moreover, the increasing integration of wearable devices and digital biomarkers in clinical trials has significantly transformed patient monitoring and data collection by enabling continuous, real-world health tracking. Devices such as smartwatches, biosensors, and remote health trackers provided real-time physiological data, allowing researchers to monitor patients outside of clinical settings, which enhanced trial accuracy and reduced the need for frequent site visits. This advancement has driven the widespread adoption of decentralized and hybrid clinical trials, enabling greater patient participation, particularly among those in remote or underserved areas.

Furthermore, the shift toward personalized medicine and patient-specific treatment approaches has significantly driven the demand for customized medical devices, particularly in fields such as orthopedics, cardiology, and oncology. The growing emphasis on tailored therapies had necessitated the development of medical devices designed to meet individual patient needs, leading to increased clinical trials focused on adaptive study designs. These trials allowed for real-time modifications based on patient-specific responses, ensuring more precise, effective, and safer outcomes. With advancements in 3D printing, AI-driven diagnostics, and biomaterial engineering, medical device manufacturers have expanded their capabilities to create highly personalized implants, prosthetics, and drug-device combinations.

Key market players are implementing strategic partnerships, product innovations, regulatory approvals, geographic expansions, and AI-driven trial solutions to strengthen their position in the Medical Device Clinical Trials market. Companies like Medtronic and Siemens Healthineers have expanded their AI-driven clinical trial ecosystems, while Abbott secured FDA approval for a label update on its HeartMate 3 LVAD to enhance patient management.

Medical Device Clinical Trials Market Report Highlights:

• Based on study type, pivotal study dominated the market due to its critical role in securing regulatory approvals. Pivotal studies provide comprehensive safety and efficacy data, serving as the final step before a device reaches commercialization.
• Based on study design, the interventional segment held the largest revenue share in 2024. Interventional studies are essential for obtaining regulatory approvals for high-risk devices, especially in areas like cardiology, orthopedics, and neurology.
• Based on Indication, cardiovascular devices held the largest revenue share in 2024due to due to the high global burden of cardiovascular diseases (CVDs) and the continuous innovation in implantable cardiac devices, stents, and valve replacement technologies.
• Based on region, North America held the dominant position in 2024 due to its strong clinical research infrastructure, high R&D investments, and the presence of leading pharmaceutical and biotechnology companies

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Purchased Database
  • 1.3.3. GVR's Internal Database
  • 1.3.4. Secondary Sources
  • 1.3.5. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Validation
  • 1.5.1. Region Wise Market: Base Estimates
  • 1.5.2. Global Market: CAGR Calculation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis (Model 1)
  • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
  • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
  • 1.6.4. Bottom-Up Approach (Model 4)
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Technological Advancements
  • 3.4.1. Integration of AI and Digital Technologies
• 3.5. Pricing Model Analysis
• 3.6. Clinical Trials Volume Analysis, 2024
  • 3.6.1. Total Number of Clinical Trials, by Region (2024)
  • 3.6.2. Total Number of Clinical Trials, by Phase (2024)
  • 3.6.3. Total Number of Clinical Trials, by Study Design (2024)
  • 3.6.4. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
• 3.7. Industry Analysis Tools
  • 3.7.1. Porter's Five Forces Analysis
  • 3.7.2. PESTEL Analysis
  • 3.7.3. COVID-19 Impact Analysis

Chapter 4. Medical Device Clinical Trials Market: Study Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Medical Device Clinical Trials Market; Study Type Movement Analysis
• 4.3. Medical Device Clinical Trials Size & Trend Analysis, by Study Type, 2018 to 2030 (USD Million)
• 4.4. Feasibility and Pilot Study
  • 4.4.1. Feasibility and pilot study market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Pivotal Study
  • 4.5.1. Pivotal study market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. FDA PMA Application
  • 4.6.1. FDA PMA application market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Post-Approval Study
  • 4.7.1. Post-Approval study market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Medical Device Clinical Trials Market: Study Design Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Medical Device Clinical Trials Market; Study Design Movement Analysis
• 5.3. Medical Device Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
• 5.4. Interventional
  • 5.4.1. Interventional market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Observational
  • 5.5.1. Observational market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Expanded Access
  • 5.6.1. Expanded Access market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Medical Device Clinical Trials Market: Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Medical Device Clinical Trials Market; Indication Movement Analysis
• 6.3. Medical Device Clinical Trials Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 6.4. Cardiovascular devices
  • 6.4.1. Cardiovascular devices market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Neurology devices
  • 6.5.1. Neurology devices market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Orthopedic devices
  • 6.6.1. Orthopedic devices market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Diagnostic imaging
  • 6.7.1. Diagnostic imaging market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Anesthesia and Respiratory devices
  • 6.8.1. Anesthesia and respiratory devices market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Others
  • 6.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Medical Device Clinical Trials Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. North America medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Germany medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. UK
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. UK medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. South Korea medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Australia medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Thailand medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait medical device clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. Abbott
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Service benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Medtronic
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Service benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Siemens Healthineers AG
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Service benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Fresenius Medical Care AG
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Service benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. GE Healthcare
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Service benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Koninklijke Philips N.V.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Service benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Danaher Corporation
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Service benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Baxter
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Service benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Boston Scientific Corporation
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Service benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. F. Hoffmann La Roche
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Service benchmarking
    • 8.3.10.4. Strategic initiatives

관련자료